Home › NDC Lookup › RxCUI directory › RxCUI 2390954

0.4 ML ofatumumab 50 MG/ML Pen Injector [Kesimpta] — RxCUI 2390954

RxNorm drug concept · Semantic branded drug
RxCUI 2390954 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2390954
Official name0.4 ML ofatumumab 50 MG/ML Pen Injector [Kesimpta]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as0.4 ML Kesimpta 50 MG/ML Pen Injector; KESIMPTA 20 MG in 0.4 ML Pen Injector; KESIMPTA 20 MG per 0.4 ML Sensoready Pen Injector
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)43,282 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ofatumumab Injection (Chronic Lymphocytic Leukemia): what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Ofatumumab — sold as Kesimpta — is used to treat relapsing forms of multiple sclerosis in adults. That includes relapsing-remitting MS, clinically isolated syndrome (a first MS-lik...
  • What exactly is this medication used for?
  • It's a subcutaneous injection — a small shot you give yourself under the skin, much like an insulin pen. You start with three injections in the first two weeks (at weeks 0, 1, and...
  • How do I actually take it — is it a pill or a shot?
📖 Read our full Ofatumumab Injection (Chronic Lymphocytic Leukemia) guide →

🕸️ Concept Web — How 0.4 ML ofatumumab 50 MG/ML Pen Injector [Kesimpt... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 0.4 ML ofatumumab 50 MG/ML Pen Injector [Kesimpta] RxCUI 2390954

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ofatumumab 712566
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Kesimpta 2390950
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ofatumumab Pen Injector 2390948
    • Ofatumumab Injectable Product 1159554
    • Ofatumumab Pen Injector [Kesimpta] 2390952
    • Kesimpta Injectable Product 2390953
    • Pen Injector 1649571
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Ofatumumab 50 MG/ML [Kesimpta] SBDC · 2390951
  • Ofatumumab Pen Injector [Kesimpta] SBDF · 2390952
  • Kesimpta Injectable Product SBDG · 2390953
  • Kesimpta BN · 2390950

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2390954 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-1007-68 1 SYRINGE, GLASS in 1 CARTON (0078-1007-68) / .4 mL in 1 SY... KESIMPTA Novartis Pharmaceuticals Corporation 2020-08-20
00078-1007-98 1 SYRINGE, GLASS in 1 CARTON (0078-1007-98) / .4 mL in 1 SY... KESIMPTA Novartis Pharmaceuticals Corporation 2020-08-20
Observed labelers: Novartis Pharmaceuticals Corporation (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$24,391.7000
Range $24,391.7000–$24,391.7000 · middle 50% $24,391.7000–$24,391.7000 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.